Stock comparison
Eli Lilly
Zoetis
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$946.37B
Sector
Healthcare
ZTS
Zoetis
Market cap
$31.17B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | ZTS | Winner |
|---|---|---|---|
| Warren Buffett | 65B | 57C | LLY |
| Benjamin Graham | 76B | 62C | LLY |
| Philip Fisher | 75B | 53C | LLY |
| Peter Lynch | 64C | 34F | LLY |
| Joel Greenblatt | 68B | 35D | LLY |
| Charlie Munger | 75B | 61C | LLY |
| Terry Smith | 66B | 65B | LLY |
Side-by-side metrics
| Metric | LLY | ZTS |
|---|---|---|
| Market cap | $946.37B | $31.17B |
| P/E (TTM) | 35.6x | 11.9x |
| EV/EBIT | 33.2x | 10.8x |
| ROIC (TTM) | 32.06% | 21.79% |
| Gross margin | 83.51% | 70.75% |
| Net margin | 34.98% | 27.79% |
| Revenue CAGR 5y | 23.17% | 5.04% |
| EPS CAGR 5y | 40.81% | 8.88% |
| Debt / Equity | 1.4x | 0.1x |
| Dividend yield | 0.64% | 2.77% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Market cap$946.37Bvs $31.17B+97%
- Revenue CAGR 5y23.17%vs 5.04%+78%
- EPS CAGR 5y40.81%vs 8.88%+78%
- ROIC (TTM)32.06%vs 21.79%+32%
ZTS leads on
- Debt / Equity0.1xvs 1.4x+96%
- Dividend yield2.77%vs 0.64%+77%
- EV/EBIT10.8xvs 33.2x+67%
- P/E (TTM)11.9xvs 35.6x+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.